New cocktail of cancer drugs shows promise for tough leukemia cases
NCT ID NCT04169737
First seen Jun 27, 2026 · Last updated Jul 17, 2026 · Updated 2 times
Summary
This phase 2 trial is testing whether a combination of three drugs—acalabrutinib, venetoclax, and obinutuzumab—can better control chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) that has come back or is resistant to treatment. About 168 adults with high-risk or relapsed disease will receive either two or three drugs. The main goal is to see if the treatment can clear cancer cells from the bone marrow.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- acalabrutinib, venetoclax, and obinutuzumab
- What this could lead to
- If successful, this combination could offer a more effective treatment option for people with hard-to-treat CLL or SLL, potentially leading to longer remission without the need for continuous therapy.
- What could go wrong
- This is a phase 2 trial, so it is still early. The drugs may cause serious side effects like infections or bleeding, and the combination might not work better than existing treatments.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECURRENT CHRONIC LYMPHOCYTIC LEUKEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
M D Anderson Cancer Center
RECRUITINGHouston, Texas, 77030, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Immunotherapy combo shows promise for Tough-to-Treat blood cancers
- Engineered immune cells take on tough blood cancers in early trial
- Triple-Target CAR T-Cells offer new hope for tough blood cancers
- Blood cancer transplant study tests safer GVHD prevention
- Stem cell transplant study seeks best way to prevent immune attack
- New Two-Step transplant shows promise for blood cancer patients